Coletti Giesler Kristen L
Be-Well Medicine Limited Liability Corporation (LLC), Kenai, AK, United States.
Front Immunol. 2025 Aug 5;16:1564788. doi: 10.3389/fimmu.2025.1564788. eCollection 2025.
Chronic Inflammatory Response Syndrome (CIRS), a complex condition triggered by environmental exposures such as mold toxins, remains challenging to treat effectively. This case study documents the incidental findings of hyperbaric oxygen therapy (HBOT) as a potential therapeutic intervention for CIRS. A 60-year-old female patient with persistent symptoms and abnormal laboratory markers underwent 40 shallow dive HBOT sessions over 10 weeks. Clinical evaluations included symptom scoring, visual contrast sensitivity (VCS) testing, and biomarker analysis, with pre-treatment tests conducted via Quest Diagnostics and post-treatment tests via LabCorp. Results demonstrated significant improvements: resolution of all 22 reported symptoms, normalization of VCS scores (from 68% to 93%), and notable reductions in inflammatory biomarkers, including TGF-β1 and MMP-9. This case illustrates HBOT's ability to modulate systemic inflammation, improve neurocognitive outcomes, and enhance recovery in patients with complex environmental illnesses. While limited to a single-patient design, this study underscores the need for extensive quantitative research to validate HBOT's efficacy in managing CIRS and similar conditions.
慢性炎症反应综合征(CIRS)是一种由霉菌毒素等环境暴露引发的复杂病症,有效治疗仍具有挑战性。本病例研究记录了高压氧治疗(HBOT)作为CIRS潜在治疗干预手段的意外发现。一名60岁女性患者,症状持续且实验室指标异常,在10周内接受了40次浅度高压氧治疗。临床评估包括症状评分、视觉对比敏感度(VCS)测试和生物标志物分析,治疗前测试通过奎斯特诊断公司进行,治疗后测试通过LabCorp进行。结果显示有显著改善:22项报告症状全部消除,VCS评分恢复正常(从68%提高到93%),炎症生物标志物包括转化生长因子-β1和基质金属蛋白酶-9显著降低。本病例说明了高压氧治疗调节全身炎症、改善神经认知结果以及促进复杂环境疾病患者康复的能力。虽然本研究限于单病例设计,但强调了开展广泛定量研究以验证高压氧治疗在管理CIRS及类似病症方面疗效的必要性。